CAR T-Cell Therapy in Multiple Meyloma Webcast 1

CE / CME

CAR T-Cell Therapy in Multiple Myeloma: Understanding and Communicating Current Evidence for CAR T-Cell Therapy

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners: 0.75 Nursing contact hours, includes 0.75 hour of pharmacotherapy credit

Released: January 30, 2025

Expiration: July 29, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

What is a key difference between CAR T-cell therapy and bispecific antibody therapy?

2.

Which of the following outcomes was reported with ciltacabtagene autoleucel in the phase III CARTITUDE-4 study comparing the CAR T-cell therapy to SoC in patients with 1-3 prior lines of therapy who were lenalidomide refractory?